The graft versus host disease (GvHD) treatment market is expected to witness robust growth over the next decade, with an estimated market size of USD 5,960.7 million by 2033. The market is projected to expand at a compound annual growth rate (CAGR) of 8.2% during the forecast period, driven by advancements in treatment options and increasing prevalence of the condition.
In 2023, the GvHD treatment market is anticipated to hold a value of USD 2,713.6 million, reflecting a steady growth trajectory from 2018 to 2022, where the market displayed an 8.2% growth rate. The rising adoption of corticosteroids and combination therapies in hematopoietic cell transplant (HCT) patients is significantly contributing to the market expansion.
Get your PDF Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1401
Orencia (abatacept) was approved by the US Food and Drug Administration in December 2021 for the treatment of GVHD in both adult and pediatric patients. Orencia is used both to prevent and cure autoimmune disorders. This medication avoids the attack of T-cells, which are crucial in acute GVHD, by selectively attaching to and altering one of the major costimulation signals sent by these cells.
As a result, acute (GVHD) is avoided since T-cells are kept from fully activating. Surgeons are assessing a number of novel strategies to stop GVHD in the future.
Key Takeaways:
- The global graft versus host disease (GvHD) treatment market is expected to reach US$5.96 billion by 2033, growing at a CAGR of 8.2%.
- Rising adoption of combination therapies and advancements in allogeneic hematopoietic cell transplant (HCT) are key growth drivers.
- Newer medications like Jakafi and Rezurock offer improved efficacy for chronic GvHD compared to traditional treatments.
Recent improvements in acute graft-versus-host disease (GVHD) severity levels and overall survival rates may be advantageous for allogeneic hematopoietic cell transplant patients; nevertheless, a number of issues still need to be resolved. Furthermore, more recent drug approvals for the prevention and treatment of chronic (GVHD) include Jakafi and Rezurock, which may be more beneficial than earlier ones.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1401
Key Segments Profiled in Market:
By Product:
- Monoclonal antibodies
- mTOR inhibitors
- Tyrosine kinase inhibitors
- Thalidomide
- Etanercept
By Disease:
- Acute Graft Versus Host Disease (aGvHD)
- Chronic Graft Versus Host Disease (cGvHD)
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/1401
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
